See more : Havells India Limited (HAVELLS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of PetVivo Holdings, Inc. (PETV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PetVivo Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Viking Energy Group, Inc. (VKIN) Income Statement Analysis – Financial Results
- Shanghai Sheng Jian Environment Technology Co., Ltd. (603324.SS) Income Statement Analysis – Financial Results
- Black Hawk Acquisition Corporation Class A Ordinary Shares (BKHA) Income Statement Analysis – Financial Results
- Smooth Rock Ventures Corp. (SMRVF) Income Statement Analysis – Financial Results
- China National Accord Medicines Corporation Ltd. (000028.SZ) Income Statement Analysis – Financial Results
PetVivo Holdings, Inc. (PETV)
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 968.71K | 917.16K | 115.59K | 12.58K | 3.59K | 77.94K | 1.51K | 7.12K | 75.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 229.18K | 526.82K | 201.15K | 10.70K | 19.71K | 77.94K | 643.39K | 746.85K | 743.63K | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 739.53K | 390.35K | -85.57K | 1.88K | -16.12K | 0.00 | -641.88K | -739.72K | -668.63K | -1.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 76.34% | 42.56% | -74.03% | 14.97% | -449.33% | 0.00% | -42,508.48% | -10,383.51% | -891.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.27M | 690.58K | 474.88K | 98.23K | 12.67K | 200.98K | 118.94K | 167.89K | 168.60K | 4.40K | 119.30K | 0.00 | 0.00 | 157.30K |
| General & Administrative | 6.69M | 5.02M | 3.15M | 1.77M | 1.23M | 3.60M | 2.17M | 16.23M | 3.16M | 1.20M | 36.85M | 82.40K | 102.40K | 103.68K |
| Selling & Marketing | 3.40M | 3.41M | 1.35M | 94.98K | 171.51K | 38.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.80K |
| SG&A | 10.09M | 8.43M | 4.50M | 1.86M | 1.40M | 3.64M | 2.17M | 16.23M | 3.16M | 1.20M | 36.85M | 82.40K | 102.40K | 105.48K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 559.54K | 646.92K | 2.17M | 16.23M | 3.16M | 0.00 | 24.44M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.36M | 9.12M | 4.97M | 1.96M | 1.97M | 4.49M | 2.29M | 16.40M | 3.33M | 1.20M | 36.97M | 82.40K | 102.40K | 262.78K |
| Cost & Expenses | 11.59M | 9.65M | 5.17M | 1.97M | 1.99M | 4.57M | 2.29M | 16.40M | 3.33M | 1.20M | 36.97M | 82.40K | 102.40K | 262.78K |
| Interest Income | 0.00 | 15.84K | 9.85K | 228.60K | 32.19K | 84.95K | 0.00 | 0.00 | 0.00 | 0.00 | 19.53K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 228.60K | 32.19K | 84.95K | 74.02K | 188.51K | 270.58K | 399.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 126.85K | 114.43K | 65.15K | 86.71K | 559.54K | 646.92K | 643.39K | 746.85K | 743.63K | 10.48K | 36.97M | 3.81K | 227.00 | 659.00 |
| EBITDA | -10.49M | -8.62M | -4.99M | -1.87M | -1.49M | -3.92M | -1.64M | -16.39M | -2.51M | -1.20M | -19.68K | -78.59K | -102.18K | -262.12K |
| EBITDA Ratio | -1,083.35% | -952.23% | -4,345.73% | -14,885.32% | -39,724.53% | -5,032.45% | -108,737.02% | -219,579.00% | -3,343.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.62M | -8.73M | -5.06M | -1.96M | -2.02M | -4.67M | -2.29M | -16.39M | -3.25M | -1.20M | -36.97M | -82.40K | -102.40K | -262.78K |
| Operating Income Ratio | -1,096.45% | -952.23% | -4,374.69% | -15,574.72% | -56,190.97% | -5,995.70% | -151,345.50% | -230,062.51% | -4,334.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -333.96K | 15.84K | 41.53K | -1.56M | -66.60K | -84.95K | -52.02K | -132.05K | -1.48M | -363.84K | -19.68K | -3.81K | -227.00 | -659.00 |
| Income Before Tax | -10.96M | -8.72M | -5.01M | -3.52M | -2.08M | -4.76M | -2.34M | -16.52M | -4.73M | -1.57M | -36.99M | -86.21K | -102.63K | -263.44K |
| Income Before Tax Ratio | -1,130.92% | -950.50% | -4,338.76% | -28,007.47% | -58,047.21% | -6,104.70% | -154,790.60% | -231,916.03% | -6,307.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.84K | -73.21K | 228.60K | 32.19K | 84.95K | 74.02K | -990.17K | -1.08M | 388.68K | -19.68K | 0.00 | 0.00 | 0.00 |
| Net Income | -10.96M | -8.70M | -4.94M | -3.75M | -2.11M | -4.76M | -2.34M | -15.53M | -3.65M | -1.57M | -36.99M | -86.21K | -102.63K | -263.44K |
| Net Income Ratio | -1,130.92% | -948.77% | -4,275.42% | -29,824.89% | -58,944.23% | -6,104.70% | -154,790.60% | -218,017.03% | -4,868.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.78 | -0.85 | -0.56 | -0.61 | -0.10 | -1.03 | -0.61 | -7.71 | -2.07 | -0.91 | -308.77 | -1.55 | -2.00 | -5.86 |
| EPS Diluted | -0.78 | -0.85 | -0.56 | -0.61 | -0.10 | -1.03 | -0.61 | -7.71 | -2.07 | -0.91 | -308.77 | -1.55 | -2.00 | -5.86 |
| Weighted Avg Shares Out | 13.97M | 10.22M | 8.76M | 6.20M | 21.22M | 4.61M | 3.81M | 2.01M | 1.77M | 1.71M | 119.81K | 55.69K | 51.37K | 44.98K |
| Weighted Avg Shares Out (Dil) | 13.97M | 10.22M | 8.76M | 6.20M | 21.22M | 4.61M | 3.81M | 2.01M | 1.77M | 1.71M | 119.81K | 55.69K | 51.37K | 44.98K |
Garry Lowenthal Joins PetVivo Holdings, Inc. as the Chief Financial Officer
MINNEAPOLIS, MN, US, March 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is...
Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that...
PetVivo Holdings, Inc. (PETV) Q3 2024 Earnings Call Transcript
PetVivo Holdings, Inc. (PETV) Q3 2024 Earnings Call Transcript
PetVivo Reports Third Quarter of Fiscal 2024 Financial Results
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results...
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy
MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024
MINNEAPOLIS, MN, US, Feb. 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Monday, February 12, 2024...
PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
MINNEAPOLIS, MN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that...
PetVivo Holdings, Inc. Invites You to Join Us at The Microcap Conference
Minneapolis, Minnesota--(Newsfile Corp. - January 11, 2024) - PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW), a company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals, will be participating in The Microcap Conference,...
PETVIVO HOLDINGS, INC. TO EXHIBIT AT VETERINARY MEETING AND EXPO CONFERENCE IN ORLANDO, FLORIDA
MINNEAPOLIS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it will be exhibiting at...
PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%
New York, December 22, 2023 – PetVivo Holdings, Inc. (Nasdaq: PETV) has achieved a distribution milestone, reporting a total of 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year. Spryng, the company's signature product, helps to manage lameness, joint pain...
Source: https://incomestatements.info
Category: Stock Reports